Anti-HPV16E7 [TVG 701Y]
Invented at University of Cambridge
- Datasheet
- References (6)
- Inventor Info
Info
Catalogue Number | 151170 |
Applications | ELISA IHC IF WB |
Antigen/Gene or Protein Targets | Human Papilloma Virus-16 early protein 7 (HPV16 E7) |
Reactivity | Human papilloma virus |
Relevance | The human papilloma virus (HPV) family of DNA tumor viruses includes HPV-16 and HPV-18, which are associated with a large proportion of cervical cancer cases. HPV early proteins E6 and E7 are the major viral oncoproteins that regulate cell proliferation through the inactivation of p53 and Rb1 tumour suppressor proteins respectively. |
Host | Mouse |
Immunogen | HPV 16 E7 synthesised from S. pombe |
Subclass | IgG2a |
Myeloma Used | P3/NS1/1-Ag4.1 |
Recommended Growing Conditions | RPMI 1640 + 15% FCS. |
Strain | Balb/c |
Research Area | Cancer, Virology |
References: 6 entries
Chen et al. 2020. Antiviral Res. 178:104794. PMID: 32298665.
WB
Kannan et al. 2017. Sci Rep. 7:46102. PMID: 28383029.
IHC WB
Harris et al. 2013. Br J Cancer. 108(4):859-65. PMID: 23385729.
IHC
Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein.
Europe PMC ID: 23385729
Tommasino et al. 1993. Oncogene. 8(1):195-202. PMID: 8380917.
HPV16 E7 protein associates with the protein kinase p33CDK2 and cyclin A.
Europe PMC ID: 8380917
Add a reference
References: 6 entries
Chen et al. 2020. Antiviral Res. 178:104794. PMID: 32298665.
WB
Kannan et al. 2017. Sci Rep. 7:46102. PMID: 28383029.
IHC WB
Harris et al. 2013. Br J Cancer. 108(4):859-65. PMID: 23385729.
IHC
Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein.
Tommasino et al. 1993. Oncogene. 8(1):195-202. PMID: 8380917.
HPV16 E7 protein associates with the protein kinase p33CDK2 and cyclin A.
Add a reference